scholarly journals TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

Oncotarget ◽  
2016 ◽  
Vol 7 (22) ◽  
pp. 32731-32753 ◽  
Author(s):  
George Fountzilas ◽  
Eleni Giannoulatou ◽  
Zoi Alexopoulou ◽  
Flora Zagouri ◽  
Eleni Timotheadou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Adjuvant Setting ◽  
Tp53 Mutations ◽  
Poor Outcome

scholarly journals High Levels of Chromosomal Copy Number Alterations and TP53 Mutations Correlate with Poor Outcome in Younger Breast Cancer Patients

2020 ◽  
Vol 190 (8) ◽  
pp. 1643-1656
Author(s):  
Ayla Koçak ◽  
Kerstin Heselmeyer-Haddad ◽  
Annette Lischka ◽  
Daniela Hirsch ◽  
David Fiedler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Copy Number ◽  
Copy Number Alterations ◽  
Breast Cancer Patients ◽  
Tp53 Mutations ◽  
Poor Outcome ◽  
Chromosomal Copy Number ◽  
Chromosomal Copy

Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jack J. Chan ◽  
Tira J.Y. Tan ◽  
Rebecca A. Dent
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Adjuvant Setting

Anthracycline-containing regimen in early breast cancer: Analysis of toxicity

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11104-11104
Author(s):  
A. I. Jagiello-Gruszfeld ◽  
A. Lowczak ◽  
J. Zbrzezniak-Smilgiewicz ◽  
S. Szablowska-Siwik ◽  
G. Licznerska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Risk Group ◽  
Internet Access ◽  
Hormonal Treatment ◽  
Intermediate Risk ◽  
Adjuvant Setting ◽  
Grade 3

11104 Background: The anthracycline-containing regimens is considered to be more beneficial to patients (pts) with early breast cancer (EBC). However at this moment is not clear which kind of regimen should be used in adjuvant setting. Methods: In our center, from Jan 2004 to Sep 2006, 248 breast cancer pts, who were qualified to the adjuvant chemotherapy received FEC100 (104 pts), AC (126 pts). or sequentially AC- taxans (18). Pts with many poor prognostic factors (N+, T3, G3, HER2/neu 3+) received 6 cycles of FEC100 or AC-taxans. Pts with better prognosis (Intermediate Risk Group according St.Gallen’s guidelines for 2005) received usually 4 cycles of AC. Besides, in most cases, internet access to the adjuvantonline! program was used during making decision. ER-ve or PR-ve positive pts received sequentially hormonal treatment. The radiotherapy (if needed) was delivered at the end of the chemotherapy. Results: During the treatment, toxicity of the chemotherapy was evaluated by NCI CTC v. 3. There was no toxic deaths. Median follow-up period was 19 months (range: 6–36). The febrile neutropenia was observed in 4 pts in FEC100 and in 5 pts in AC group. There was also no significant differences in the grade 3 or 4 neutropenia, anemia, thrombocytopenia and alopecia. In 3 pts treated with FEC100 and 1 with AC, cardiotoxicity grade 2 or 3 was diagnosed. Grade 2 or 3 asthenia was frequent in FEC100 group (44% vs 21% vs11%). In all pts prophylaxis of nausea/vomiting was used. However pts treated with FEC100 needed more 5HT3. Vomiting grade 2 or 3 were observed significantly more often in pts who received FEC100 (58% vs 26% vs 23%). Only at 1 pts in each group the chemotherapy was interrupted due to toxicity (asthenia gr 3, vomiting gr 3 and weight loss gr 2). The relative dose intensities of FEC100 and AC were 87% and 96% of planned doses, respectively. Conclusions: The acute symptoms of toxicity were important for breast cancer pts who received the adjuvant chemotherapy. According the adjuvantonline! 6 cycles of FEC100 were more effective than 4 cycles of AC. Nevertheless tolerability of AC is better. Many pts prefer only the hormonal treatment, even if it is not the optimal option, in fear of nausea or vomiting. The ongoing clinical trials should further define the best choice of anthracycline-containing regimen in the adjuvant setting. No significant financial relationships to disclose.

Is a high number of uninvolved nodes in early breast cancer an indicator of poor outcome?

2001 ◽  
Vol 37 ◽  
pp. S187
Author(s):  
V. Vinh-Hung ◽  
G. Cserni ◽  
T. Burzykowski ◽  
J. Van de Steene ◽  
G. Storme
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Poor Outcome

scholarly journals How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer

Breast Care ◽  
2013 ◽  
Vol 8 (4) ◽  
pp. 264-269
Author(s):  
Ana Catarina Pinto ◽  
Evandro de Azambuja ◽  
Martine Piccart-Gebhart
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Optimal Timing ◽  
Adjuvant Setting

Personalizing Locoregional Treatment in the Adjuvant Setting of Early Breast Cancer on the Basis of Molecular Background: An Exciting Enigma

2011 ◽  
Vol 29 (35) ◽  
pp. 4721-4722 ◽  
Author(s):  
Pelagia G. Tsoutsou ◽  
Wendy Jeanneret Sozzi ◽  
Oscar Matzinger ◽  
Mahmut Ozsahin
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Adjuvant Setting ◽  
Locoregional Treatment
Sign in / Sign up

Export Citation Format

Share Document